Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole in High-Risk Patients With Invasive Fungal Infections in Slovakia
2017-000501-20Phase 4
- Sponsor
- Pfizer
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of voriconazole in invasive mycoses and mycoses, sponsored by Pfizer. Primary endpoint: Clinical and/or mycological efficacy at end of treatment.
02
Drugs
voriconazole
03
Conditions
invasive mycosesmycoses
Beyond the preview
Go deeper on 2017-000501-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000501-20.